Neuralink clinical trials
Answer 7 short questions to see which Neuralink studies may fit you or someone you care for, the nearest trial hospitals, and how to apply.
This is an informal guide, not medical advice. Neuralink and each study's doctors decide who can take part, after their own screening. A "possible match" here does not mean you qualify, and a "not a match" does not mean you never will.
Your answers stay in this browser tab. Nothing is stored or sent anywhere, and the answers clear when you reload the page.
The registry entries for PRIME, CAN-PRIME, GB-PRIME, UAE-PRIME, and VOICE share most of their requirements. Each also lists a working ability to communicate in English and a life expectancy of at least 12 months. These usually rule a person out:
Neuralink and each study's investigators decide. After a person joins the Patient Registry, Neuralink reviews the information, and candidates who look suitable go through medical screening with the trial site. This checker only compares answers with the published criteria.
Neuralink's trials page says participation has zero financial cost: the care, device, and procedure are provided, and study travel is covered for the participant and a caregiver, as described in the informed consent.
Join Neuralink's Patient Registry at portal.neuralink.com. It is the same form for every study and every country, and Neuralink contacts people who may fit an open study.
The FDA gave Neuralink's Blindsight vision implant Breakthrough Device designation in September 2024. As of October 7, 2026, no Blindsight study appears on ClinicalTrials.gov or on Neuralink's trials page, so the Patient Registry is the way to hear when one opens.
No. The results are worked out by code running in your browser. Neura Pod does not record, store, or send the answers, and reloading the page clears them.
Criteria come from the study records on ClinicalTrials.gov: PRIME, CAN-PRIME, GB-PRIME, UAE-PRIME, VOICE, CONVOY, and the Shirley Ryan AbilityLab assessment study. Neuralink's own pages: clinical trials, device control, and speech restoration. Blindsight designation: Spectrum News, September 2024. Trial hospitals come from Neura Pod's clinical trial locations.
Criteria last checked October 7, 2026. Where Neuralink's website and a registry entry differ, the checker shows "Ask Neuralink". See also the Neuralink FAQ and the patient profiles.
